key: cord-0277787-52bgtiz4
authors: Santopaolo, Marianna; Sullivan, Niall; Thomas, Anita C.; Alvino, Valeria; Nicholson, Lindsay; Gu, Yue; Spinetti, Gaia; Kallikourdis, Marinos; Blom, Ashley; Madeddu, Paolo
title: Activation of bone marrow adaptive immunity in type 2 diabetes: rescue by co-stimulation modulator Abatacept
date: 2020-07-04
journal: bioRxiv
DOI: 10.1101/2020.07.03.187088
sha: 89eb81f25023a791d8d1eb4b55b76def3213ff04
doc_id: 277787
cord_uid: 52bgtiz4

Hypothesis Type 2 diabetes (T2D) is characterized by low-grade inflammation. Here, we investigated the state of adaptive immunity in bone marrow (BM) of patients and mice with T2D. We also tested if inhibition T cell co-stimulation by Abatacept could rescue the immune profile of T2D mice. Methods Flow-cytometry and cytokine analyses were performed on BM samples from patients with or without T2D. Moreover, we studied the immune profile of db/db and control wt/db mice. A cohort of db/db mice was randomized to receive Abatacept or vehicle for 4 weeks, with endpoints being immune cell profile and indexes of insulin sensitivity and heart performance. Results T2D patients showed increased frequencies of BM CD4+ (2.8-fold, p=0.001) and CD8+ T cells (1.8-fold, p=0.01), with upregulation of the activation marker CD69 and homing receptor CCR7 in CD4+ (1.64-fold, p=0.003 and 2.27-fold, p=0.01, respectively) and CD8+ fractions (1.79-fold, p=0.05 and 1.69-fold, p=0.02, respectively). CCL19 (CCR7 receptor ligand) and CXCL10/11 (CXCR3 receptor ligands), implicated in T cell migration and activation, were the most differentially modulated chemokines. Studies in mice confirmed the activation of adaptive immunity in T2D. Abatacept reduced the activation of T cells and levels of pro-inflammatory chemokines and cytokines. Additionally, Abatacept improved indexes of cardiac systolic function, but not insulin sensitivity. Conclusions These novel findings support the concept of BM adaptive immune activation in T2D. Modulation of T cell co-stimulation could represent an attractive and immediately available modality to dampen inappropriate activation of adaptive immune response and protect from target organ damage.

What is already known?

• Type 2 diabetes is characterized by systemic low-grade inflammation and activation of innate immunity

• The bone marrow, a primary lymphoid organ, is populated by a variety of immune cells, including regulatory cells, antigen presenting cells, activated T cells, and memory T cells.

• In people with type 2 diabetes, the bone marrow incurs progressive remodeling, with inflamed fat cells prevailing over hematopoietic cells along with pauperization of the vascular niche.

• Modulation of antigen presentation to immune competent cells exerts beneficial effects in autoimmune disease, which has led to propose extending the use of immune modulators to chronic conditions characterized by an inflammatory substrate.

What is the key question?

• Does BM remodelling involve an alteration of T lymphocyte abundance and local cytokine production, shifting immune response toward a cytotoxic phenotype?

• Can modulation of T cell co-stimulation rescue inappropriate immune responses in obese, type 2 diabetic mice?

What are the new findings?

• Patients and mice with type 2 diabetes show a shift in the prevalent subsets of bone marrow T lymphocytes, with an enrichment of activated cells.

• Treatment of obese, type 2 diabetic mice with Abatacept rescued the altered adaptive immune profile and improved heart performance, without improving insulin sensitivity.

• The bone marrow requires clinical attention as a target and trigger of inflammatory responses involving cells of the adaptive immunity.

• Use of immune modulatory drugs can be envisaged to suppress excessive immune response and improve cardiac function in type 2 diabetes.

Chronic low-grade inflammation plays an important role in the progression of type 2 diabetes mellitus (T2D) and in the increased propensity of diabetic people to develop cardiovascular disease, infections, and cancer [1] [2] [3] [4] Both innate and adaptive immunity play key roles in the development of metabolic inflammation and insulin resistance [5] [6] [7] [8] [9] [10] [11] .

The presence of T lymphocytes in various organs, especially the visceral adipose tissue (VAT), correlates with progression and severity of T2D [12] [13] [14] . On the one hand, VAT hampers the number and function of anti-inflammatory Treg cells and promotes immune responses by the CD4 + and CD8 + T cells, including those with an autoreactive potential [15] . On the other hand, T cells infiltrating the adipose tissue play key roles in the regulation of mechanisms at the intersection of metabolism and immune tolerance [16] , contributing to a vicious cycle that leads to the loss of metabolic control through deterioration of pancreatic β cell function [17, 18] . It is therefore imperative to investigate the root of the problem in organs directly implicated in the production and maturation of immune cells.

The bone marrow (BM) is a primary lymphoid organ (the other being the thymus), i.e. a site where immune cells are formed, mature, and/or recirculate [19, 20] . These comprise subsets with important and specific functionalities, such as T cells, B cells, dendritic cells (DCs) and macrophages. The BM also contains memory T cells that maintain a state of readiness after tissue injury; they can rapidly expand and mount a robust secondary cytotoxic response in case of new challenges, more potently than that afforded by other lymphoid and non-lymphoid organs [21, 22] . T cells can home to the BM from the circulation and persist within this organ contributing to systemic immune memory [23] .

Moreover, the BM contains central CD4 Foxp3 Tregs, which suppress effector T cells, but also exert non-immune actions, such as vascular protection, metabolic homeostasis, and tissue repair [24, 25] . Immune regulation occurs in the BM through direct cell-cell contacts and soluble factors, including cytokines and chemokines. Paracrine crosstalk between immune cells and other BM cells influences T cell trafficking, retention, and activation.

Despite this consolidated knowledge, little is known about the impact of T2D on BM immune cell composition and function. A number of studies have shown that people with T2D incur a remarkable remodeling of BM, consisting of accumulation of inflamed adipocytes and depletion of hematopoietic, neuronal, and vascular cells [26] [27] [28] [29] . These changes impinge on hematopoietic cell functions and contribute in altering the profile and mobilization capacity of hematopoietic stem/progenitor cells (HSPCs) [30, 31] . An altered phenotype of released HSPCs reportedly conveys antiangiogenic and proapoptotic features to the peripheral vasculature, thereby contributing to diabetic complications [32] .

Based on this background, we posit that T2D could also impact on BM immune cell homeostasis.

The aim of the present study was to determine the frequencies of immune cell subsets in the BM of patients with T2D compared with non-diabetic individuals, with focus on activated and memory T cells. After confirming human results in a murine model of T2D, we used Abatacept, a modulator of T cell co-stimulation, to rescue the abnormalities in adaptive immunity and cytokine secretion.

Patients undergoing hip replacement surgery were recruited under informed consent at the T2D was diagnosed according to the American Diabetes Association guidelines.

Specifically, it was defined as 1) patient/referring doctor reports a previous diagnosis of diabetes and 2) HbA 1c >48 mmol/mol. We excluded subjects with acute disease/infection, inflammatory/immune diseases, current or past haematological disorders or malignancy, unstable angina, recent (within 6 months) myocardial infarction or stroke, heart failure, liver failure, dialysis, and pregnancy.

BM samples were obtained from scooped femur heads remaining from hip replacement surgery. Only material that would otherwise be discarded was collected for study. During the replacement procedure, the femoral head was removed with a saw, and the proximal femoral canal was opened with reamers and rasps. The BM displaced into the wound was scooped into a sterile pot with a curette. The sample was decanted into a collection tube with 0.5 mol/L EDTA, pH 8 (ThermoFisher, Gloucester, UK, #28348) labelled, and placed in a fridge for collection by the investigator within 1 hour.

The diluted BM suspension was passed through a 100-μm filter to remove bone provided water ad libitum. Glucose was measured in urine using Diastix colorimetric reagent strips (Bayer, Reading, U.K.). At sacrifice, BM, spleen, and peripheral blood were collected according to the procedures described below.

Abatacept [250 mg lyophilized powder per vial, Bristol-Myers Squibb (Princeton, NJ)] was purchased from the Bristol University Hospital Pharmacy. The drug was reconstituted at 2X of the concentration required in sterile distilled water (25 mg/mL). The vial was gently swirled until complete dissolution of the compound. The reconstituted material was diluted with sterile pH-checked PBS for in vivo use on the same day of preparation.

A cohort of twelve 10-week-old male db/db mice was randomized to treatment with Abatacept or vehicle. Mice were injected intraperitoneally with 300 μg Abatacept in 100 μ L PBS, three non-consecutive times a week, for 4 weeks, while controls received the vehicle. The dosage and control choice was adapted from a previous Abatacept study in a murine model of cardiomyopathy [33] . Dimensional and functional parameters of the heart were measured before sacrifice using a Vevo3100 echocardiography system, using a MX400 transducer (Fujifilm VisualSonics Inc, Toronto, Canada). The echocardiography study was performed with mice under isoflurane anaesthesia (2.5% for induction, followed by 0.5-1.2% as appropriate to maintain heart rate between 400 and 450 bpm).

At sacrifice, whole BM cells were obtained from the mouse tibiae and femora. Both ends of the bones were cut using sterile, sharpened scissors. BM cells were harvested by repeated flushing of the bone shaft in 1mL PBS in a tube using a syringe provided with a 23-gauge needle. After removal of aggregates from the BM suspension by vigorous pipetting and filtration through a 70μm mesh nylon strainer (#07-201-431, Fisher scientific), the sample was centrifuged at 300g for 10 min. The pellets were resuspended to obtain a suspension of 2 x 10 6 cells/mL in fresh PBS for use in cytometry analysis.

Supernatants were collected for cytokine assays and stored at −20°C.

Mononuclear spleen suspensions were prepared by gently pressing the spleen tissue with the flat end of a syringe in 5 mL of RPMI containing 1% pen/strep, on a 100mm culture dish. Then, cell suspension was passed through on a 70-µm cell strainer into a 50 mL tube. After washing twice with 5 mL RPMI, the cell suspension was centrifuged at 300g for 10 min, and cells were resuspended in Bioscience™ 1X RBC Lysis Buffer (#00-4333-57) on ice for 3 min. Finally, splenocytes were washed, resuspended in PBS at a concentration of 2 × 10 6 cells/mL, and counted.

At sacrifice, blood was harvested with an EDTA-coated syringe from the left ventricle and placed into Eppendorf tubes. Blood was centrifuged for 15 min at 3,000 rpm (1500xg) at 4 • C. After centrifugation, plasma was removed, and the pellet incubated with 1X RBC Lysis Buffer on ice for 10 min. Mononuclear cells were then resuspended at 2 x 10 6 cells/mL in PBS. Plasma was stored at -80°C for later analysis. were detected by exposing the membrane to X-ray film, which was subsequently developed with ChemiDoc XRS+ System by Bio-Rad. The mean luminescence was 1 normalized to reference spots from the same membrane following background correction.

Pixel densities on developed X-ray film were analyzed using Fiji -ImageJ image analysis software.

Plasma levels of insulin and glucose were measured using colorimetric assay kits (from Thermo Fisher, #EMINS, and Abcam, #ab65333, respectively). Quantitative insulin sensitivity check index (QUICKI) was calculated according to the formula QUICKI = 1/(logI0 + logG0), where I is insulin (μU/mL) and G is glucose (nmol/μL). In addition, the HOMA-IR formula was calculated as fasting insulin multiplied by fasting glucose divided by 22.5.

Values are presented as mean ± standard error of the mean (SEM). Two-tailed independent-samples T-test was used to compare groups with T2D and without diabetes.

ANOVA was used in multiple comparisons and was followed by post-hoc Sidak's multiple comparisons test. P values <0.05 were considered statistically significant.

The two studied groups were similar regarding age and sex distribution (Supplementary Table 1 ). The analysis was performed on BM cells from data of the CD45/SSC gating, where lymphocytes showed the highest CD45 fluorescence intensity and the lowest SSC signal (Figure 1A-C) . Cell viability was consistently >90% (Figure 1B) . There were no differences in the total cellularity (data not shown) and frequency of CD45 cells between T2D and ND groups (Figure 1C , p=0.88). We next analyzed lymphocytes, namely T cells (CD45 + CD3 + ), NK cells (CD45 + CD16 + CD56 + ), and B cells (CD45 + CD19 + ) using the gating strategy shown in Figure 1D . This characterization demonstrated an increase in the 

T cells are activated through presentation of antigens expressed on the surface of antigenpresenting cells (APCs). Once activated, they divide rapidly and secrete cytokines that regulate and sustain the immune response. Previous studies have shown that the human BM contain T cells in the activated state as denoted by the expression of CD69 [34] . Here, we report that BM CD4 + and CD8 + T cells from patients with T2D have a heightened activation state compared with ND individuals, as indicated by an increased frequency of CD69 (Figure 2A) . The highest expression of CD69 was observed in the CD4 + fraction, which was increased 3.64-fold in T2D (p=0.003 vs. ND), while the increase was 1.79-fold for the CD8 + fraction (p=0.05 vs. ND) (Figure 2B-C) . We looked for confirmation of T cell activation by checking the expression of the late marker CD25. Data indicate a more modest difference between the two groups, not reaching statistical significance (p=0.15 and 0.07, for CD4 + and CD8 + cells, respectively) (Figure 2D-E) .

The CC-chemokine receptor 7 (CCR7) and its ligands play a key role in lymphocyte homing to lymphoid tissue. In the T2D group, both CD4 + and CD8 + lymphocytes expressed CCR7 with higher frequency than the ND group (2.27-fold, p=0.01; and 1.69-fold, p=0.02, respectively) (gating shown in Figure 2A and results in Figure 2F-G) . Moreover, we combined CCR7 and CD45RA antigens in the flow cytometry analysis to distinguish naïve and memory subpopulations (gating strategy shown in Figure 3A ). Naive CCR7 + CD45RA + T cells were more abundant in T2D, with 19.9 ± 5.4% of the CD4 + cell subfraction expressing this phenotype (2.46-fold more than ND, p=0.04) (Figure 3B) . Within CD8 + cells, naive T lymphocytes averaged 16.2 ± 3.2% (1.76-fold more than ND, p=0.09) ( Figure 3C) A multivariable regression model including age and sex as covariates confirmed the differences detected using the univariate analysis. Table 2 ). An analysis conducted using the STRING database revealed that most of the differentially regulated factors were connected in a network with a PPI enrichment p-value: < 1.0e-16 ( Figure 4B) . Interestingly, in the cytokine series, IL-18 and IL-31 were the most upregulated (both over 13-fold). Among chemokines, CXCL10 and CXCL11 (CXCR3 receptor ligands), MCP-1 (CCR2 ligand), and CCL19 (CCR7 receptor ligand), which are implicated in T cell migration to site of inflammation, emerged as the most upregulated factors (all over 3.5-fold). Twenty-six proteins were modulated, including VEGF-A, Complement C5, and EGF (all showing an increase > 14-fold). Moreover, Basigin (alias CD147), which functions as a receptor for soluble cyclophilins and is involved in cyclophilin-mediated viral infection [35] , was upregulated in T2D, together with its transcriptional target MMP-9. Whereas LIF, an inhibitor of immune response afforded by T lymphocytes [36] , and CD40L, a costimulatory ligand for CD80 involved in repression/modulation of lymphocyte activation [37] , were downregulated. Analysis of covariance detected a strong overall effect of T2D on the analysed factors (p<0.001).

Multiple comparison analysis documented a significant difference regarding VEGF-A (p=0.03), Basigin (p=0.01), Chitinase-3-like protein 1 (p=0.003), and Insulin-like growth factor-binding protein 2 (p=0.008).

We next sought confirmation about the influence of T2D on immune cells by assessing the phenotype of different cell populations in BM, spleen, and peripheral blood from 10-weekold db/db and control wt/db mice ( Figure 5A) . Confirmation of the diabetic state in the db/db group was achieved by verification of persistent overt glycosuria. Flow cytometry analysis demonstrated db/db mice had substantial increases in the frequency of CD4 + and CD8 + cells in BM (1.88-fold, p=0.02; and 2.23-fold, p=0.005, respectively), spleen (1.53fold, p<0.0001; 1.27-fold, p=0.04, respectively) and peripheral blood (1.66-fold, p=0.007; and 1.71-fold, p=0.004) (Figure 5B-C) , which were associated with decreased abundance of CD19 + B cells in the BM (0.67-fold, p<0.0001), but not in spleen or peripheral blood ( Figure 5D ). Regarding NK cells, higher numbers were found in BM of db/db mice (1.77fold, p=0.01), whereas no difference was observed in the other two districts (Figure 5E ).

We also extended the analysis beyond lymphocytes to macrophages, identified as CD11b + F4/80 + cells; they were more abundant in db/db mice at the level of BM (9.25±0.89 vs. 5.77±0.58% in wt/db, p=0.04) and peripheral blood ( We next assessed specific subsets of CD4 + and CD8 + cells using immunostaining for the marker of activation CD25. No difference between db/db and wt/db mice was observed regarding CD4 + cells (data not shown). In contrast, as shown in Figure 5F , higher levels of CD8 + cells stained positive for CD25 in db/db mice at the level of the BM (3.87-fold, p=0.02) but not in the spleen or peripheral blood. Finally, we determine the expression of CD103, an integrin that identifies tissue-resident-memory CD8 + cells with an immunosurveillance and protective function [38] , and is dynamically involved in the functional differentiation of some cytotoxic T cells [39] . As shown in Figure 5G , CD8 + CD103 + cells were higher in db/db mice at the level of all examined tissue (p<0.01).

CD4 + and CD8 + cells were further categorized into naïve and memory phenotypes based on the expression CD44 and CD62L, with the CD44 -CD62L high population being considered naïve, CD44 high CD62 high population considered TCM, and the CD44 high CD62L neg population considered TEM ( Figure 6A ).

Naïve cells were increased in BM of db/db mice (CD4 + : 2.70-fold, p=0.02; CD8 + :

1.44-fold p=0.01), unaltered in the spleen, and reduced in peripheral blood (CD4 + : 0.71fold, p=0.26; CD8 + : 0.64-fold, p=0.0002), which resulted in the abrogation of the peripheral to BM gradient seen in control mice (Figure 6B-C) .

TCM cells did not show differences between groups. Nonetheless, db/db mice manifested a positive gradient between BM and peripheral blood (CD4 + : 2.98-fold, p=0.0005; CD8 + : 1.49-fold, p=0.004) compared with control mice, which did not show a difference between the two districts (CD4 + : p=0.13; CD8 + : p=0.32) (Figure 6D-E) . CD4 + TEM cells were less abundant in BM of db/db mice (0.61-fold, p<0.0001) but unchanged in the other districts ( Figure 6F ). There was no difference between groups concerning CD8 + TEM cells (Figure 6G ). Table 3) . Results indicate the presence of an inflammatory environment in BM, which may account for the recruitment and activation of immune cells.

Altogether the above findings show a state of inflammation in patients and mice with T2D. This involves activation of adaptive immunity, as evidenced by the increase in CD25 + T cells and corroborated by the upregulation of a multitude of inflammation-associated mediators.

We next investigated the effect of the in vivo administration of Abatacept, a CTLA4-Ig fusion protein, on the immune profile of db/db mice. Flow cytometry analysis demonstrated that Abatacept induced an increase in the levels of CD4 + and CD8 + cells in peripheral blood (p<0.01 for both comparisons) and, limited to CD8 + cells, in BM (p=0.003), whereas no change was detected in the spleen (Figure 7A-C) . The treatment did not affect the abundance of CD19 + B lymphocytes (data not shown). These changes in relative cell subsets abundance could be a side-effect of changes in chemokine expression after co-stimulation blockade. [40] Yet, most importantly, Abatacept reduced the proliferation (judged by marker Ki67) of CD4 + T cells in BM, spleen, and peripheral blood, as well of CD8 + T cells in the periphery (Figure 7D-E) . Corroborating these findings, the levels of activation marker CD25 expressed by CD4 + T cells in BM and spleen were suppressed by the anti-inflammatory action of Abatacept (p<0.01 for both comparisons, Figure 7F ) though this was not seen in CD8 + T cells ( Figure 7G) . Moreover, Abatacept reduced the frequency of CD4 + and CD8 + cells expressing CD103 in all the districts examined ( Figure 7H-I) .

Examining the cytokine and chemokine production using a Proteome Profiler Mouse Cytokine Array, we did not find any major differences in the BM between Abatacept and control-treated animals ( Figure 7J) . However, in a manner compatible with the systemic effect of Abatacept [33] , the drug led to relative reduction in the peripheral blood levels of key classical (type 1) pro-inflammatory cytokines Il-1b and Il-12, and chemokines Cxcl9, We further analyzed the abundance of antigen presenting cells. Abatacept decreased the number of dendritic cells in peripheral blood (3.3±0.4 vs. 7.3±1.2% in vehicle, p<0.05). but did not alter the frequency of macrophages (data not shown). Finally, we examined the effect of Abatacept on naïve and memory T cells (Figure 8A) . Regarding naïve cells, the Abatacept-treated group showed a borderline increase of the CD4 + fraction in BM (p=0.05), whereas naïve CD8 + cells were unaltered (Figure 8B-C) . CD4 + TEM cells were reduced by Abatacept in BM and spleen (p<0.0001 for both comparisons), whereas CD8 + TEM cells were decreased only in BM (p=0.04). Figure 8 D-E) . TCM cells followed a more heterogeneous behaviour, the CD4 + fraction being reduced in the spleen (p=0.02) and the CD8 + fraction in peripheral blood (p=0.04). (Figure 8 F-G) .

Body weight and the weight of heart and spleen were similar between groups given vehicle or Abatacept (Figure 9A-B) . Likewise, there was no difference in the fasting levels of insulin and glucose (data not shown, as well as in indexes of insulin sensitivity HOMA-IR and QUICKI (Figure 9C-D) . In contrast, Abatacept induced an improvement in echocardiographic indexes of systolic function (Figure 9C-D) . Specifically, there Abatacept-treated mice showed higher cardiac output (CO, p<0.001) and stroke volume (SV, p<0.01), which could be reconducted to an increased preload, as suggested by the increased left ventricular end diastolic volume (EDV, p<0.01). However, Abatacept did not reduce the left ventricular mass, thus discarding an anti-hypertrophic effect of the drug.

The role of BM in the maintenance of antigen-experienced adaptive immune cells is well documented as reviewed in [41] . Moreover, immune response is altered in patients with T2D, with the most apparent cellular changes occurring in adipose tissue, pancreatic islets, and vasculature [9] . In the present study, we provide novel evidence of the activation of adaptive immunity in BM of patients and mice. In particular, the studied human diabetic cohort had an increased frequency of BM T lymphocytes, which expressed early markers of activation, and of NK cells. Moreover, both CD4 + and CD8 + lymphocytes abundantly expressed CCR7, which together with the observed high levels CCL19 (CCR7 receptor ligand) suggests that the local BM environment was reshaped to favor immune cell recruitment from peripheral tissues. We also showed that the diabetic BM contains TCM cells that have undergone recent activation. Most importantly, BM T cells showed clear upregulation of typical activation markers. Several features of the adaptive immunity activation seen in patients were confirmed in db/db mice. Importantly, we demonstrated for the first time that treatment with Abatacept, which interferes with the co-stimulation signalling mechanism systemically, inhibited the activation of adaptive immunity and improved cardiac function in db/db mice.

Abundant fat depots of overweight/obese patients reportedly contain autoreactive T cells that exert cytotoxic effect on adipocytes and fuel adipose inflammation [42, 43] .

Adipose tissue is also contiguous with main lymphoid organs, such as lymph nodes, thymus, and BM, participating in multiple intertwined mechanisms [44] . For instance, adipocytes surrounding the thymus may influence T cell differentiation in response to metabolic challenges [45] . Likewise, adipocytes that reside in the BM are thought to play relevant roles in haematopoiesis, lymphopoiesis, and memory B and T cell responses [22] .

BM adiposity becomes more abundant with aging, in parallel with decline of immunity and hematopoietic functions [46] . Fat accumulation reported by us in the BM of patients and animal models with T2D could represent a significant difference [26, 28, 47] . In fact, the analysis of BM cells indicates a reactive adaptive immunity. This cellular phenotype was associated with alterations in the levels of cytokines and chemokines that influence the lodging and activation of naïve T cells and maintenance of a memory reservoir. It remains to be ascertained whether adaptive immunity was induced by the previous exposure to foreign antigens or could be reconducted to a dysregulation of co-signalling mechanisms that direct T cell function and fate following antigen presentation. Interestingly, we found that CD147 was upregulated in the diabetic BM. This immunoglobulin acts as the main upstream stimulator of matrix metalloproteinases and may have pathogenic roles in diabetic complications, through recruitment of immune cells. Inhibition of this molecular axis reportedly exerts beneficial effects on inflammatory diseases [48] . Intriguingly, CD147

is considered a key route for SARS-CoV-2 invasion of immune cells [49] , which may account for susceptibility of diabetic patients to viral infection [50] .

The co-signalling factor CTLA4 exerts competitive inhibition of T cell activation [37] .

The regulation of CTLA4 is complex and still incompletely investigated. Induction of the CTLA-4 gene in lymphocytes is dependent on NFAT binding to the proximal promoter [51] .

Moreover, the CTLA-4 promoter is associated with transcriptionally active histones and is a candidate target for several microRNAs. Polymorphisms of the CTLA-4 gene resulting in reduction of mRNA levels have been reported in patients with Graves' disease, autoimmune hypothyroidism, and autoimmune diabetes [52] . The importance of CTLA4 as a regulator of immune response in T2D was confirmed by results of Abatacept treatment in db/db mice, showing the drug led to the systemic inhibition of T cell activation and suppressed the production of several key inflammatory cytokines and chemokines. The clinical indication of Abatacept is to treat active rheumatoid arthritis, but there are seminal data supporting its potential in cardiovascular disease. Abatacept reportedly improved cardiac function in mice with pressure overload-induced heart failure, through inhibition of activation and cardiac infiltration of cytotoxic T cells and macrophages, leading to reduced cardiomyocyte death [33] . Moreover, recent case reports showed Abatacept treatment led to resolution of glucocorticoid-refractory myocarditis caused by rheumatoid arthritis or immune checkpoint inhibitor anti-cancer treatment [53] . Here, we showed that, although not sufficient to improve insulin resistance, the anti-inflammatory action of Abatacept could benefit cardiac function of db/db mice, improving preload and stroke volume.

In conclusion, we newly showed the state of adaptive immunity activation in diabetic BM and the possibility to rescue immune and cardiac abnormalities using the clinically available, immune-modulatory drug Abatacept. These results may have important clinical and therapeutic implications. However, the study has some limitations and warrants additional investigation. The observed differences in the frequency of immune cells were 2 0 substantial and highly significant. However, studies in large cohorts of patients are required to reach definitive conclusions and determine whether activation of adaptive immune cells in BM is a general phenomenon or characterizes specific subgroups of diabetic patients according to disease duration and severity. Such an Investigation should be complemented by mechanistic research on the causes responsible for T cell activation.

Finally, studies in models of diet-induced diabetes could strengthen the novel evidence provided by data from the genetically diabetic db/db mice. 

Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. The Lancet

Diabetes Is Associated With Decreased Limb Survival in Patients With Critical Limb Ischemia: Pooled Data From Two Randomized Controlled Trials

The diabetes-cancer link

Inflammageing and metaflammation: The yin and yang of type 2 diabetes

Hotamisligil GS: Inflammation, metaflammation and immunometabolic disorders

Inflammaging: a new immune-metabolic viewpoint for age-related diseases

White blood cells count as an indicator to identify whether obesity leads to increased risk of type 2 diabetes

High glucose induces toll-like receptor expression in human monocytes: mechanism of activation

Role of Adaptive and Innate Immunity in Type 2 Diabetes Mellitus

Role of T Lymphocytes in Type 2 Diabetes and Diabetes-Associated Inflammation

B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies

Distinct macrophage populations direct inflammatory versus physiological changes in adipose tissue

Obesity Expands a Distinct Population of T Cells in Adipose Tissue and Increases Vulnerability to Infection

Immune Cells Gate White Adipose Tissue Expansion

Antigen-and cytokine-driven accumulation of regulatory T cells in visceral adipose tissue of lean mice

Type 2 Diabetes: How Much of an Autoimmune Disease? Front Endocrinol (Lausanne) 2019

A guide to immunometabolism for immunologists

The bone marrow is not only a primary lymphoid organ: The critical role for T lymphocyte migration and housing of long-term memory plasma cells

The bone marrow at the crossroads of blood and immunity

Activation of bone marrowresident memory T cells by circulating, antigen-bearing dendritic cells

Bone Marrow T Cells and the Integrated Functions of Recirculating and Tissue-Resident Memory T Cells. Front Immunol

The bone marrow: a nest for migratory memory T cells

New insights into the mechanisms of Treg function

Dominant Role for Regulatory T Cells in Protecting Females Against Pulmonary Hypertension

Global remodeling of the vascular stem cell niche in bone marrow of diabetic patients: implication of the microRNA-155/FOXO3a signaling pathway

Role for substance p-based nociceptive signaling in progenitor cell activation and angiogenesis during ischemia in mice and in human subjects

MCP-1 Feedback Loop Between Adipocytes and Mesenchymal Stromal Cells Causes Fat Accumulation and Contributes to Hematopoietic Stem Cell Rarefaction in the Bone Marrow of Patients With Diabetes

Diabetes causes bone marrow endothelial barrier dysfunction by activation of the RhoA-Rho-associated kinase signaling pathway

Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment

Diabetes-Associated Myelopoiesis Drives Stem Cell Mobilopathy Through an OSM-p66Shc Signaling Pathway

Proapoptotic Signaling From Circulating CD34(+) Cells to Vascular Endothelial Cells: A Potential Contributor to Adverse Cardiovascular Outcomes in Patients With Critical Limb Ischemia

Ormbostad Berre AM, Stolen TO et al: T cell costimulation blockade blunts pressure overload-induced heart failure

Human bone marrow: a reservoir for "enhanced effector memory" CD8+ T cells with potent recall function

CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement

LIF in the regulation of T-cell fate and as a potential therapeutic

Diverse mechanisms regulate the surface expression of immunotherapeutic target ctla-4

The Emerging Role of CD8(+) Tissue Resident Memory T (TRM) Cells in Antitumor Immunity: A Unique Functional Contribution of the CD103 Integrin

A Yin and Yang in Epithelial Immunology: The Roles of the alphaE(CD103)beta7 Integrin in T Cells

Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis

A T Cell View of the Bone Marrow

Obesity and susceptibility to autoimmune diseases

The changes in immune cell concentration during the progression of pre-diabetes to type 2 diabetes in a high-fat highcarbohydrate diet-induced pre-diabetic rat model

Metabolic pressure and the breach of immunological self-tolerance

A: The intricate interface between immune system and metabolism

Grubeck-Loebenstein B: The aging bone marrow and its impact on immune responses in old age

Bone marrow fat: friend or foe in people with diabetes mellitus?

Monocyte CD147 is induced by advanced glycation end products and high glucose concentration: possible role in diabetic complications

CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China

Role of transcription factor NFAT in glucose and insulin homeostasis

Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease

Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis